M&T Bank Corp Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS)

M&T Bank Corp purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,700 shares of the company’s stock, valued at approximately $667,000.

A number of other hedge funds also recently bought and sold shares of the business. FMR LLC raised its stake in Krystal Biotech by 0.5% during the fourth quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. increased its position in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after acquiring an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after acquiring an additional 6,600 shares during the last quarter. Hood River Capital Management LLC increased its position in Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company’s stock valued at $80,324,000 after acquiring an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Krystal Biotech by 16.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock valued at $79,812,000 after acquiring an additional 71,200 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, June 24th. Guggenheim cut their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Citigroup restated a “neutral” rating and issued a $176.00 price target (up from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. Finally, Chardan Capital restated a “buy” rating and issued a $219.00 price target on shares of Krystal Biotech in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus price target of $213.75.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 6,927 shares of the stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $150.27, for a total transaction of $1,040,920.29. Following the completion of the sale, the insider directly owned 1,525,929 shares of the company’s stock, valued at approximately $229,301,350.83. This represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 13,927 shares of company stock worth $2,092,852 over the last ninety days. Corporate insiders own 13.70% of the company’s stock.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $147.73 on Wednesday. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $219.34. The company has a 50-day moving average of $135.75 and a 200 day moving average of $156.11. The firm has a market cap of $4.27 billion, a PE ratio of 35.51 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The business had revenue of $88.18 million during the quarter, compared to analysts’ expectations of $98.66 million. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).